Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Apollo Commercial Real Estate Finance Liquidating Trust Divestiture
Apollo Commercial Real Estate Finance, Inc. (ARI) completed its plan of liquidation by transferring all remaining assets and liabilities to the Apollo Commercial Real Estate Finance Liquidating Trust. ARI stockholders received non-transferable units of beneficial interest in the trust on a one-for-one basis, and ARI's common stock has been cancelled and deregistered from the SEC.
Rank One Computing M&A Deal with Zuccaro Technical Consulting LLC
Rank One Computing Corporation (ROC) filed this amendment to provide required audited and pro forma financial statements following its completed acquisition of Zuccaro Technical Consulting LLC (ZTC). The transaction, which closed on August 31, 2026, involved ROC acquiring all issued and outstanding membership interests of ZTC from ZTC Holdco, Inc.
Fulcrum Therapeutics Signs $7M M&A Deal with Slate Medicines, Inc.
Fulcrum Therapeutics entered into an agreement to sell its early-stage fetal hemoglobin (HbF) assets to an unaffiliated third-party pharmaceutical company for $7.0 million in cash. The sale is a strategic update to its pending merger with Slate Medicines, as the proceeds will be credited to Fulcrum's net cash and are expected to increase the cash dividend declared in connection with the merger.
Lineage Cell Therapeutics Signs $2.4M M&A Deal with NeuroAirmid Therapeutics, Inc.
Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics, Inc., adding a clinical-stage neural cell therapy program (HUNT1) for Huntington’s Disease to its pipeline. The deal involved a $2.4 million upfront cash payment and the assumption of a co-funding obligation for an ongoing Phase 1b/2a clinical study supported by CIRM.
Value
$2.4M
Counterparty
NeuroAirmid Therapeutics, Inc.
“Today, we closed the acquisition of NeuroAirmid Therapeutics adding HUNT1, a third clinical-stage asset to our development pipeline. HUNT1 is a pluripotent stem cell derived, clinical-stage neural cell therapy program, with the potential to validate a new cell-based treatment modality for Huntington’s Disease.”
Brian M. Culley, Lineage CEO
“This transaction reflects the disciplined approach to capital allocation and strategic fit that we believe our investors have come to expect from Lineage. HUNT1 was created on the same proprietary cell line that Lineage uses and is compatible with its AlloSCOPE “5D” technology, providing us with a head start on our planned contributions.”
Neuronetics, Inc. entered into an underwriting agreement to sell 18,750,000 shares of common stock at a public offering price of $1.60 per share. The company also granted underwriters a 30-day option to purchase an additional 2,812,500 shares, bringing the total potential gross proceeds to approximately $34.5 million. Net proceeds will be used to repay a portion of outstanding term loans under its Perceptive Credit Facility and for general corporate purposes.
Launch Two Acquisition M&A Deal with NuCube Energy, Inc.
Launch Two Acquisition Corp. (SPAC) has filed an updated investor presentation regarding its previously announced pending business combination with NuCube Energy, Inc. The presentation is intended for use in meetings with institutional investors and analysts to discuss the proposed merger and NuCube's microreactor technology for industrial and data center energy needs. The parties have already filed a Registration Statement on Form S-4 as they work toward closing the transaction.
Applied Optoelectronics completed the $102.25 million acquisition of three buildings at Hightower Business Park in Houston, Texas, totaling approximately 736,216 square feet. The company exercised purchase options in its existing leases to secure the facilities for manufacturing, warehouse, and office use, subsequently terminating the related lease agreements.
GoPro entered into an amendment to its existing merger agreement with Action Acquisition LLC, extending the deal's outside closing date from December 31, 2026, to March 31, 2027. The amendment also includes technical adjustments for potential stock splits or reclassifications and corrects a scrivener's error regarding the parent company's name. Parent is required to seek an extension of its financing commitment letter to match the new March 2027 deadline.
Integral Technologies M&A Deal with Apex North LLC
Integral Technologies, Inc. completed the acquisition of an 80% membership interest in Apex North LLC, a mining company owning 394 unpatented lode claims in Utah. The transaction is structured as a reverse merger, causing the company to cease being a shell company and resulting in a change of control. Apex North's assets include the Apex North Critical Minerals Project covering approximately 8,141 acres of BLM-administered land.
WF Card Issuance Trust, an entity sponsored by Wells Fargo Bank, completed the issuance of its Class A(2026-2) Notes on November 12, 2026. In connection with the closing, the depositor reported a Transferor Interest of approximately $4.12 billion to satisfy U.S. credit risk retention requirements.
Honda Auto Receivables 2026-4 Owner Trust Capital Raise
Honda Auto Receivables 2026-4 Owner Trust completed the issuance and sale of Class A-1, A-2a, A-2b, A-3, and A-4 Asset Backed Notes. The transaction involved the transfer of retail installment sale contracts for Honda and Acura automobiles from American Honda Finance Corporation to the issuing entity through a series of definitive agreements including an Indenture and Sale and Servicing Agreement.
Forgent Power Solutions delivered a significant Q1 beat and raised FY2027 guidance, emphasizing that data center demand remains resilient despite post-election regulatory uncertainty and supply constraints.
Forgent Power Solutions delivered a record-breaking fiscal 2026, significantly exceeding IPO forecasts and guidance while doubling manufacturing capacity and revenue to support surging AI-driven data center demand.
Bluerock Homes Trust completed the sale of 25 single-family residential units from its Golden Pacific portfolio to unaffiliated third parties for an aggregate price of approximately $6.6 million. This transaction is part of a larger disposition program that has seen the company sell a total of 86 units from the Indiana, Kansas, and Missouri portfolio throughout 2026. The company realized net proceeds of approximately $5.9 million from this specific tranche of sales after closing costs and adjustments.
Ondas is scaling rapidly through aggressive M&A and vertical integration, targeting $1.1 billion revenue in 2027 while pivoting toward sovereign AI and high-demand defense platforms.
Virtuix Holdings Signs $12M M&A Deal with STS International Inc.
Virtuix Holdings Inc. signed a non-binding letter of intent to acquire defense technology firm STS International for $12 million in cash and equity. The deal aims to establish a new 'Virtuix Defense' division, leveraging STS's $40 million in year-to-date revenue and established government contract vehicles. The transaction is expected to close by March 31, 2027, subject to definitive agreements and audited financial reviews.
Vishay Intertechnology Partnership with Kaynes Technology India Limited Worth $56.4M
Vishay Intertechnology entered into a binding term sheet with Kaynes Technology India Limited to establish a semiconductor manufacturing joint venture in India. Vishay will invest $56.4 million for a 49% interest in the JV, which will focus on back-end manufacturing capabilities including wafer processing, assembly, and testing. The parties intend to apply for government support under the India Semiconductor Mission 2.0 program.
Stockholders of Daré Bioscience approved the potential future issuance of common stock upon the exercise of outstanding warrants in accordance with Nasdaq listing rules. The approval was obtained at a special meeting held on November 10, 2026, ensuring compliance with dilution limits for a previously initiated capital raise.
NEXGEL announced a strategic recapitalization and update on a potential merger with Fountainhead LifeSciences, including its affiliates Sequence LifeScience and NVISION Biomedical Technologies. As part of the plan, holders of $14.125 million in convertible notes (95% of outstanding principal) agreed to convert their debt into common stock at $5.50 per share, contingent upon the completion of the merger.
Boxlight stockholders approved several proposals at a special meeting, including the issuance of shares exceeding 19.99% of outstanding stock related to Series D and Series E Preferred Stock financings and an equity line of credit. These approvals satisfy Nasdaq Listing Rule 5635(d) and are part of the company's plan to maintain compliance with Nasdaq's stockholders' equity requirements. The company expects to receive $2 million from the second tranche of its Series D financing and begin utilizing a $15 million equity line of credit.
MetaVia announced additional positive data from Part 3B of its Phase 1 clinical trial of DA-1726, demonstrating a statistically significant 1.47 mg/dL placebo-adjusted reduction in serum uric acid after 16 weeks. These results complement previously reported data showing a 68.1% reduction in liver fat and 13.5% weight loss, supporting the drug's advancement into a Phase 2 study for MetALD and ALD planned for late 2027.
Nano Mobile Healthcare M&A Deal with Neptune Engineering Limited
Nano Mobile Healthcare provided a status update on its pending acquisition of Neptune Engineering (Marine) Limited, which is now expected to close in the fourth quarter of 2026. The company filed unaudited pro forma condensed combined financial information reflecting the transaction, which involves issuing 20 million shares of common stock to acquire Neptune and raise cash from investors.
Investcorp Credit Management BDC M&A Deal with BCP Investment Corporation
Investcorp Credit Management BDC (ICMB) has entered into a definitive agreement to be acquired by BCP Investment Corporation (BCIC). ICMB stockholders will receive aggregate consideration equal to 90% of ICMB’s net asset value at closing, paid primarily in BCIC shares (capped at 19.99% of BCIC's outstanding stock) with the remainder in cash.
Counterparty
BCP Investment Corporation
“This transaction marks another step in executing our vision of driving consolidation across the BDC sector. We have long believed that greater scale can deliver meaningful benefits, and the combination of ICMB and BCIC is expected to generate immediate cost synergies, lower financing costs and improved trading liquidity.”
Ted Goldthorpe, Chief Executive Officer and Chairman of the Board of BCIC
“This transaction reflects ICMB’s longstanding commitment to pursuing optimal returns for our stockholders. We believe the combination with BCIC positions the Company to deliver long-term value for stockholders. ICMB’s size and scale have been challenging to navigate in current market conditions.”
Suhail A. Shaikh, President and Chief Executive Officer of ICMB
BCP Investment M&A Deal with Investcorp Credit Management BDC, Inc.
BCP Investment Corp (BCIC) has entered into a definitive agreement to acquire Investcorp Credit Management BDC, Inc. (ICMB) in a merger transaction. ICMB stockholders will receive consideration equal to 90% of ICMB's net asset value at closing, paid primarily in BCIC shares with a cash component if the share issuance exceeds a 19.99% cap. The deal is intended to drive sector consolidation and generate cost synergies through increased scale.
Counterparty
Investcorp Credit Management BDC, Inc.
“This transaction marks another step in executing our vision of driving consolidation across the BDC sector. We have long believed that greater scale can deliver meaningful benefits, and the combination of ICMB and BCIC is expected to generate immediate cost synergies, lower financing costs and improved trading liquidity. We believe these benefits will position the combined company to deliver stronger long-term value for stockholders.”
Ted Goldthorpe, Chief Executive Officer and Chairman of the Board of BCIC
“This transaction reflects ICMB’s longstanding commitment to pursuing optimal returns for our stockholders. We believe the combination with BCIC positions the Company to deliver long-term value for stockholders. ICMB’s size and scale have been challenging to navigate in current market conditions. We believe that a combination with BCIC provides our stockholders the benefits of scale and access that Sierra Crest brings in the private credit market.”
Suhail A. Shaikh, President and Chief Executive Officer of ICMB
Ellington Financial Inc. completed the sale of its mortgage servicing rights (MSR) related investments and excess servicing spread investments to an unaffiliated third party. The assets were originally acquired through the 2023 acquisition of Arlington Asset Investment Corp. and the sale is expected to free up more than $75 million in cash for redeployment into core strategies.
Neuronetics, Inc. entered into an underwriting agreement to sell 18,750,000 shares of common stock at $1.60 per share, with an additional 2,812,500 shares available via an underwriters' option. The company expects to raise approximately $30 million in gross proceeds ($27.7 million net) to repay debt under its Perceptive Credit Facility and for general corporate purposes.
M2i Global Signs $100M M&A Deal with Happy Growth Group Limited
M2i Global entered into a definitive agreement to acquire 100% of Graphex Technologies LLC (GTL) from Happy Growth Group Limited for $100 million. The purchase price consists of $3 million in cash (via a note) and $97 million in common stock tranches tied to the delivery of a design and completion of a 50,000 metric ton per year graphite anode production plant in the U.S. The acquisition includes an exclusive license to 30 patents for natural graphite anode production across North America.
HeartCore Enterprises Partnership with ONE AI Co., Ltd.
HeartCore Enterprises entered into a non-exclusive business development and sales agency agreement with ONE AI Co., Ltd. to bring the Axis.ONE physical AI platform to industrial robots in Japan. The partnership aims to retrofit existing factory equipment with CPU-native, on-device AI capabilities for vision and decision-making without requiring GPU clusters or cloud dependency.
GT Biopharma shareholders approved a significant increase in authorized common shares from 25 million to 250 million and authorized the issuance of more than 19.99% of outstanding stock. These approvals facilitate the conversion of Series M Preferred Stock and the exercise of warrants related to a Securities Purchase Agreement dated September 14, 2026. The vote ensures compliance with Nasdaq Rule 5635 regarding the potential dilution from these previously announced financing transactions.
VisionWave Holdings Signs $7M M&A Deal with Europostachservice LLC
VisionWave Holdings entered into a non-binding Letter of Intent to acquire a 51% controlling interest in EPSERVICE, a Ukrainian developer of unmanned aerial systems and 'mothership' drone control technology. The proposed acquisition from Metal Machinery Components Trading – FZCO involves $7 million in cash consideration payable 90 days after closing. The deal is subject to technical due diligence in Ukraine, including a live flight demonstration of the ICMM system.